Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

253 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors.
Maurea N, Coppola C, Piscopo G, Galletta F, Riccio G, Esposito E, De Lorenzo C, De Laurentiis M, Spallarossa P, Mercuro G. Maurea N, et al. Among authors: de lorenzo c, de laurentiis m. J Cardiovasc Med (Hagerstown). 2016 May;17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection:e19-e26. doi: 10.2459/JCM.0000000000000377. J Cardiovasc Med (Hagerstown). 2016. PMID: 27755239 Review.
Combination of inositol and alpha lipoic acid in metabolic syndrome-affected women: a randomized placebo-controlled trial.
Capasso I, Esposito E, Maurea N, Montella M, Crispo A, De Laurentiis M, D'Aiuto M, Frasci G, Botti G, Grimaldi M, Cavalcanti E, Esposito G, Fucito A, Brillante G, D'Aiuto G, Ciliberto G. Capasso I, et al. Among authors: de laurentiis m. Trials. 2013 Aug 28;14:273. doi: 10.1186/1745-6215-14-273. Trials. 2013. PMID: 23981814 Free PMC article. Clinical Trial.
Metabolic syndrome-breast cancer link varies by intrinsic molecular subtype.
Capasso I, Esposito E, de Laurentiis M, Maurea N, Cavalcanti E, Botti G, Petrillo A, Montella M, D'Aiuto M, Coppola C, Crispo A, Grimaldi M, Frasci G, Fucito A, Ciliberto G, D'Aiuto G. Capasso I, et al. Among authors: de laurentiis m. Diabetol Metab Syndr. 2014 Sep 26;6(1):105. doi: 10.1186/1758-5996-6-105. eCollection 2014. Diabetol Metab Syndr. 2014. PMID: 25285159 Free PMC article.
Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors.
Maurea N, Coppola C, Piscopo G, Galletta F, Riccio G, Esposito E, De Lorenzo C, De Laurentiis M, Spallarossa P, Mercuro G. Maurea N, et al. Among authors: de lorenzo c, de laurentiis m. J Cardiovasc Med (Hagerstown). 2016 May;17 Suppl 1:S19-26. doi: 10.2459/JCM.0000000000000377. J Cardiovasc Med (Hagerstown). 2016. PMID: 27183521 Review.
Cardiotoxicity and pro-inflammatory effects of the immune checkpoint inhibitor Pembrolizumab associated to Trastuzumab.
Quagliariello V, Passariello M, Coppola C, Rea D, Barbieri A, Scherillo M, Monti MG, Iaffaioli RV, De Laurentiis M, Ascierto PA, Botti G, De Lorenzo C, Maurea N. Quagliariello V, et al. Among authors: de lorenzo c, de laurentiis m. Int J Cardiol. 2019 Oct 1;292:171-179. doi: 10.1016/j.ijcard.2019.05.028. Epub 2019 May 17. Int J Cardiol. 2019. PMID: 31160077
Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study.
Buono G, Crispo A, Giuliano M, De Angelis C, Schettini F, Forestieri V, Lauria R, De Laurentiis M, De Placido P, Rea CG, Pacilio C, Esposito E, Grimaldi M, Nocerino F, Porciello G, Giudice A, Amore A, Minopoli A, Botti G, De Placido S, Trivedi MV, Arpino G. Buono G, et al. Among authors: de angelis c, de placido s, de placido p, de laurentiis m. Breast Cancer Res Treat. 2020 Jul;182(2):401-409. doi: 10.1007/s10549-020-05701-7. Epub 2020 Jun 4. Breast Cancer Res Treat. 2020. PMID: 32500397 Free PMC article.
NLRP3 as Putative Marker of Ipilimumab-Induced Cardiotoxicity in the Presence of Hyperglycemia in Estrogen-Responsive and Triple-Negative Breast Cancer Cells.
Quagliariello V, De Laurentiis M, Cocco S, Rea G, Bonelli A, Caronna A, Lombari MC, Conforti G, Berretta M, Botti G, Maurea N. Quagliariello V, et al. Among authors: de laurentiis m. Int J Mol Sci. 2020 Oct 21;21(20):7802. doi: 10.3390/ijms21207802. Int J Mol Sci. 2020. PMID: 33096896 Free PMC article.
The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin.
Quagliariello V, De Laurentiis M, Rea D, Barbieri A, Monti MG, Carbone A, Paccone A, Altucci L, Conte M, Canale ML, Botti G, Maurea N. Quagliariello V, et al. Among authors: de laurentiis m. Cardiovasc Diabetol. 2021 Jul 23;20(1):150. doi: 10.1186/s12933-021-01346-y. Cardiovasc Diabetol. 2021. PMID: 34301253 Free PMC article.
Rare tumours of the breast.
Esposito E, De Laurentiis M. Esposito E, et al. Among authors: de laurentiis m. Transl Cancer Res. 2019 Oct;8(Suppl 5):S443-S444. doi: 10.21037/tcr.2019.10.05. Transl Cancer Res. 2019. PMID: 35117120 Free PMC article. No abstract available.
253 results